We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Aptamers for Cancer Diagnosis and Therapy

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Aptamers for Cancer Diagnosis and Therapy"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AMSBIO offer an extensive range of aptamers targeting many human proteins linked to cancer. Aptamers bind to target molecules with the same affinity and specificity as antibodies but offer significant advantages, in particular a lack of immunogenicity, which makes them an ideal tool for cancer diagnosis and therapy.

There are two major applications for aptamers in cancer therapy. Aptamers can be used as antagonists by targeting and inhibiting cancer-specific molecules. They can also be used as delivery vehicles for therapeutics by specifically targeting cell membrane receptors on cancer cells. In this application, aptamer-drug conjugates bind to and are internalized by cancer cells while avoiding damage to healthy cells.

Aptamers also have enormous potential for use in cancer diagnostics. They can be used to identify cancer cells and recognize cancer biomarkers, cancer metabolites and differentiating cells as well as molecules that affect tumor behavior. New aptamer-based technologies such as cell-SLEX are increasingly being used to screen for aptamers that bind to cancer cell-surface protein biomarkers as they overcome the traditional shortfalls of mass spectrometry and antibody-based methods - cross-reactivity, poor reproducibility, complexity, and high cost.